Last edition
News about "MHLW approval"
Japan Approves Bayer's Sevabertinib for HER2-Mutant NSCLC
Japan approves Bayer’s sevabertinib as the first targeted therapy for HER2-mutant NSCLC, including first-line use, based on phase 1/2 SOHO-01 results.
MHLW Approval | 25/08/2026 | By News Bureau
Sanofi Secures Japan Approval for Subcutaneous Formulation of Sarclisa
Sanofi’s Sarclisa subcutaneous formulation has been approved in Japan for patients with multiple myeloma. The approval is supported by the Phase 3 IRAKLIA study and marks the second global approval after the EU.
MHLW Approval | 22/06/2026 | By News Bureau | 128
Chugai Pharma's Avastin Secures Approval in Japan for Additional Indication
Chugai Pharma’s Avastin has received approval in Japan for an additional indication, becoming the world’s first therapeutic option for neurofibromatosis type 2. The approval is supported by positive phase 2 clinical study results.
MHLW Approval | 22/06/2026 | By News Bureau | 109
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy